Patient Access & Affordability
  • About
    • Mission
    • Team
    • Professional Advisory Council
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
ICER’s Latest: A draft evidence report on new treatment for Beta Thalassemia

ICER’s Latest: A draft evidence report on new treatment for Beta Thalassemia

Apr 27, 2022

On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This is the first step in ICER’s review process; ICER is scheduled to release a final report on this treatment in July 2022. Beta thalassemia is a disease...
Businesses With High-Value, Low-Cost Health Insurance Receive First-Ever Health Plan Hero Awards

Businesses With High-Value, Low-Cost Health Insurance Receive First-Ever Health Plan Hero Awards

Apr 21, 2022

Six small businesses from across the country were among the first companies ever to receive a national award for their innovative, outstanding employer-sponsored health program. The companies received the 2022 Health Plan Hero award in a ceremony recently held in the...

Categories

  • Blog
  • Comments
  • ICERWatch
  • News
  • Opinion
  • QALY
  • Research
  • Resources
  • Statements
  • Uncategorized
  • Video

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS